Grifols (GRFS) Long-Term Investments (2009 - 2025)
Grifols' (GRFS) quarterly Long-Term Investments came in at $112.9 million in Q4 2025, up 53.14% YoY from $73.7 million in Q4 2024, and up 53.14% on a QoQ basis from $73.7 million in Q4 2024.
Grifols (GRFS) Long-Term Investments (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Long-Term Investments data on file, last reported at $112.9 million in Q4 2025.
- Quarterly Long-Term Investments rose 53.14% year-over-year to $112.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $112.9 million (up 53.14% YoY) and the FY2025 annual result came in at $112.9 million, up 1781.87% from the prior year.
- Long-Term Investments climbed to $112.9 million in Q4 2025, from $73.7 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $1.8 billion in Q4 2021 to a low of $73.7 million in Q4 2024.
- A 5-year average of $786.5 million and a median of $453.0 million in 2023 frame the typical range for Long-Term Investments.
- Annual changes were most pronounced in 2021 — Long-Term Investments soared 423.86% — and 2024, when it tumbled 83.72%.
- Tracing GRFS's Long-Term Investments over 5 years: stood at $1.8 billion in 2021, then retreated by 13.39% to $1.5 billion in 2022, then slumped by 70.36% to $453.0 million in 2023, then plunged by 83.72% to $73.7 million in 2024, then soared by 53.14% to $112.9 million in 2025.
- The last three Long-Term Investments figures came in at $112.9 million (Q4 2025), $73.7 million (Q4 2024), and $453.0 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | - |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 266.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.22 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 69.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 297.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | - |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 1.56 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 135.51 Mn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | 112.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 112.91 Mn |
| Dec 31, 2024 | 73.73 Mn |
| Dec 31, 2023 | 452.97 Mn |
| Dec 31, 2022 | 1.53 Bn |
| Dec 31, 2021 | 1.76 Bn |
| Dec 31, 2020 | -544.88 Mn |
| Sep 30, 2020 | 194.29 Mn |
| Mar 31, 2020 | 504.50 Mn |
| Dec 31, 2019 | 126.71 Mn |
| Sep 30, 2019 | 156.09 Mn |
| Mar 31, 2019 | 147.46 Mn |
| Dec 31, 2018 | 258.99 Mn |
| Sep 30, 2018 | 15.48 Mn |
| Jun 30, 2018 | 45.28 Mn |
| Mar 31, 2018 | 134.15 Mn |
| Dec 31, 2017 | 257.87 Mn |
| Jun 30, 2017 | 22.56 Mn |
| Dec 31, 2016 | 4.05 Mn |
| Sep 30, 2016 | 100.76 Mn |
| Jun 30, 2016 | 98.35 Mn |